Plasmid vector and method for simultaneously displaying three polypeptides or proteins on MS2-VLP surface

By simultaneously displaying polypeptides and proteins on the MS2 VLP surface, the limitations of displaying a single type of protein in the prior art are solved, and high-sensitivity detection and the preparation of multi-epitope vaccines are achieved, which enhances the application potential of biodetection and vaccines.

CN119020385APending Publication Date: 2024-11-26GUANGZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411212205.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the prior art, MS2 VLP surfaces can display only one type of polypeptide or protein, limiting their application potential in biological detection and vaccine preparation.

Method used

By fusing polypeptide 1 in the middle of the single-chain dimer of CP protein, fusing exogenous protein 2 at the carboxy terminus, and 3 at the amino terminus of protein A, the plasmid vector is designed to achieve the MS2 VLP surface simultaneously displaying polypeptide 1, polypeptide 2 and protein. 3, and improve display efficacy by enzymatic biotinylation and purification of labels.

Benefits of technology

The MS2 VLP surface simultaneously displays three different types of peptides or proteins, which improves detection sensitivity and the application potential of multi-epitopes for vaccine preparation, and enhances the binding ability of the detection target.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020385A_ABST
    Figure CN119020385A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and particularly relates to the technical field of display of protein or polypeptide on the surfaces of phage-like particles. Aiming at the defects in the prior art, the invention breaks through the limitation that only one type of polypeptide or protein is displayed on the surface of MS2-VLP in the prior art, and provides a plasmid vector and a method for simultaneously displaying three polypeptides or proteins on the surface of MS2-VLP. And the protein 3 is fused with the amino terminal of the protein A, so that three different polypeptides or proteins, namely the polypeptide 1, the polypeptide 2 and the protein 3, are simultaneously displayed on the surface of the MS2VLP. The technical scheme can be applied to preparation of multi-epitope vaccines aiming at the same pathogen or tumor, or preparation of multi-combined vaccines by expressing epitopes of different pathogens or tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to the technical field of displaying proteins or polypeptides on the surface of phage-like particles. Background Art

[0002] In biochemistry, biotinylation is the process of covalently attaching biotin to proteins, nucleic acids, or other molecules. Biotin binds to streptavidin or avidin with extremely high affinity, rapid on-rate, and high specificity, and these interactions are exploited in many areas of biotechnology to isolate biotinylated molecules of interest. The binding of biotin to streptavidin / avidin is resistant to extreme heat, pH, and proteolysis, making it possible to capture biotinylated molecules in a variety of environments. In addition, multiple biotin molecules can be coupled to a target protein, allowing for the binding of multiple streptavidin, avidin, or neutravidin protein molecules and increasing the sensitivity of target protein detection.

[0003] Proteins can be biotinylated chemically or enzymatically. Chemical biotinylation utilizes various coupling chemistries to produce non-specific biotinylation of amines, carboxylates, sulfhydryls, and carbohydrates (e.g., NHS coupling biotinylates any primary amine in a protein). Enzymatic biotinylation results in bacterial biotin ligase biotinylating specific lysines within a specific sequence. Enzymatic biotinylation is milder than chemical biotinylation, has better specificity, and is more likely to maintain protein activity.

[0004] Biotin-labeled antibodies are widely used in biological detection. The biotinylation process usually uses the chemical biotin method, and each antibody molecule is labeled with about 2-3 molecules of biotin, that is, 1 antibody is conjugated with 2-3 molecules of biotin. The detection system based on biotin has obvious advantages, including 1) high sensitivity: the strong affinity and signal amplification effect of streptavidin can achieve high-sensitivity biological molecule detection; 2) good specificity: the biotin-streptavidin system has a high specificity, which can effectively reduce background noise and improve the accuracy of detection; 3) wide range of applications: this technology can be applied to various types of biological molecule detection, including nucleic acids, proteins, cell surface markers, etc. Increasing the number of biotin molecules labeled with antibody molecules can significantly improve the sensitivity of biological detection. Its limitations are also obvious, 1) the preparation cost of the antibody biotin-streptavidin system is relatively high, which may limit its application in some fields; 2) complex operation: antibody biotinylation technology involves multiple steps and has high requirements for experimental operation.

[0005] Traditional antibodies have high preparation costs and there are differences in potency between different batches. Nanobodies are derived from single-domain antibodies that only contain the VHH domain in camelid antibodies. They have advantages that traditional antibodies cannot match, such as good specificity, strong binding force, small molecules, high stability, and simple production.

[0006] MS2 VLP (MS2 Virus Like Particle) is an artificial virus-like particle based on the transformation of MS2 bacteriophage (host is Escherichia coli). MS VLP has simple components and clear formation mechanism. In short, it includes three components: CP protein, mature protein A and RNA carrying pac sequence (pac RNA). Among them, the 2-mer formed by 2 CP molecules interacts with the pac RNA sequence to trigger spontaneous assembly, and finally 90 CP 2-mers and 1 molecule of A protein form virus-like particles that encapsulate exogenous RNA. MS2-VLP has good stability and its particle cavity can also encapsulate exogenous RNA. Therefore, it has been widely studied and applied in nucleic acid standards, drug delivery, subunit vaccines, etc. However, the surface of the above-mentioned MS2 VLP only displays one type of polypeptide or protein, which limits the application of MS2 VLP in biological detection and vaccine preparation.

[0007] Since CP protein or single-chain dimer CP protein can be used for the preparation of MS2 VLP, there are many options for the sites of exogenous peptides or proteins displayed in MS2 VLP, including the N or C terminus of CP protein, and the N, C or middle position of single-chain dimer CP protein. Robert A et al. confirmed that random peptides up to 24 amino acids can be inserted into the AB loop at the N-terminus of MS2 CP protein, but it often destroys the ability of the coat protein to fold correctly, leading to instability caused by aggregation or proteolytic degradation. David S. Peabody et al. (1997) fused the two subunits of MS2 CP protein dimer to form a single-chain dimer of CP protein, which improved the tolerance of VLP to the insertion of exogenous peptides. Lukai Zhai et al. (2017) inserted different HPV L2 epitopes into the N terminus of MS2 CP protein single-chain dimer and successfully constructed vaccines for multiple HPV types. P. Mikel et al. fused the peptide His Tag tag in the middle of the CP protein single-chain dimer to optimize the purification of MS2 VLP. In the prior art, proteins displayed on the surface of MS2 VLP are all one type of polypeptide or protein. Summary of the invention

[0008] In view of the shortcomings of the prior art, the purpose of the present invention is to break through the limitation of the prior art that only one type of polypeptide or protein is displayed on the surface of MS2 VLP, and to realize the simultaneous display of polypeptide 1, polypeptide 2 and protein 3, three different polypeptides or proteins, on the surface of MS2 VLP. The present invention fuses polypeptide 1 in the middle of the CP protein single-chain dimer, fuses exogenous protein 2 at the carboxyl end, and fuses protein 3 with the amino end of protein A, so as to realize the simultaneous display of polypeptide 1, polypeptide 2 and protein 3, three different polypeptides or proteins, on the surface of MS2 VLP.

[0009] The invention provides a plasmid vector, which is characterized in that: the plasmid vector at least contains a packaging sequence, an MS2 bacteriophage single-chain dimer CP gene sequence and coding sequences of polypeptides 1 and 2 to be displayed, a coding sequence of protein 3 and a coding sequence of protein A; the packaging sequence is shown as SEQ ID NO.1, the coding sequence of polypeptide 1 is located in the middle of the CP protein single-chain dimer, an amber codon TAG and the coding sequence of polypeptide 2 are adjacent to the 3' end of the CP protein single-chain dimer coding sequence, the CP gene at least contains a sequence encoding a protein as shown in SEQ ID NO.2, the coding sequence of protein 3 is adjacent to the 5' end of the coding sequence of protein A, and the protein A sequence is shown as SEQ ID NO.3.

[0010] Specifically, in order to facilitate the purification of proteins expressed in the plasmid vector, a purification tag polyhistidine is fused to the carboxyl terminus of the polypeptide 2 coding sequence in the above plasmid vector.

[0011] Specifically, in order to improve the efficiency of the plasmid vector in displaying polypeptide 2, a linker sequence is added between the amber codon TAG of the plasmid vector and the coding sequence of polypeptide 2, and the amino acid encoded by the linker sequence contains glycine.

[0012] Preferably, in order to improve the yield of MS2 phage display expressed after plasmid vector transformation, the plasmid vector has a promoter at the 5' end of the coding sequence of the MS2 phage single-chain dimer CP gene and the polypeptide 1 and polypeptide 2 to be displayed.

[0013] Preferably, the above promoter is an arabinose promoter, and its sequence is shown in SEQ ID NO.5.

[0014] Preferably, in order to improve the efficiency of the plasmid vector in displaying protein 3, a linker sequence is added between protein 3 and protein A, and the amino acid encoded by the linker sequence contains glycine.

[0015] Specifically, the sequence of the plasmid vector is shown as SEQ ID NO.6.

[0016] The method for displaying three different types of polypeptides or proteins on the surface of MS2 VLP provided by the present invention comprises the following steps:

[0017] (1) constructing a plasmid vector;

[0018] (2) The plasmid vector constructed in step (1) is transferred into competent cells for expression to obtain MS2 VLPs displaying polypeptide 1, polypeptide 2 and protein 3 on the surface.

[0019] Furthermore, the present invention provides a method for displaying three different types of polypeptides or proteins on the surface of MS2 VLP, wherein the competent cell is an amber mutant Escherichia coli, such as E. coli XL1blue.

[0020] Furthermore, the MS2 VLP surface marker biotin provided in the protein display method of the invention, wherein the polypeptide 1 coding sequence contains an Avi Tag coding sequence as shown in SEQ ID NO.7, further comprising the following steps:

[0021] (3) The bacterial cells in step (2) were crushed, and the supernatant was purified by nickel column to obtain MS2

[0022] VLP;

[0023] (4) The purified MS2 VLPs were subjected to in vitro bioremediation in a BirA enzymatic reaction.

[0024] Variant

[0025] Beneficial Effects

[0026] The present invention simultaneously displays three proteins or polypeptides on the surface of MS2 VLP. This technology can be applied to prepare multi-epitope vaccines against the same pathogen or tumor, or to prepare multi-combination vaccines by expressing epitopes of different pathogens or tumors, or to label the surface of MS2 VLP with multiple biotins by displaying Avi Tag sequences.

[0027] The present invention provides a "three-display" technology, which can realize the simultaneous display of three different polypeptides or proteins, polypeptide 1, polypeptide 2 and protein 3, on the surface of MS2 VLP in a variety of ways. Wherein polypeptide 1 contains an Avi tag, which can be enzymatically biotinylated and displayed on the surface of MS2 VLP in large quantities, polypeptide 2 can contain a purification tag, or a purification tag and an Avi tag, which can be used for the purification and biotinylation of MS2 VLP, and protein 3 can be fused with protein A of MS2 VLP to monovalently display exogenous proteins or nano antibodies, which can be used to bind to the target to be detected. Based on the above design, one molecule of protein 3 can be labeled with multiple biotins for the exogenous protein or nano antibody to improve the detection sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 It is a schematic diagram of the structure of the key sequence of the plasmid vector in a specific embodiment of the present invention;

[0029] Figure 2 A picture of the detection results of a specific embodiment of the present invention. DETAILED DESCRIPTION

[0030] In order to enable ordinary technicians in this research field to better understand the present invention, the present invention is further described below in conjunction with specific embodiments and drawings. The specific embodiments are not used to limit the present invention.

[0031] The reagents and consumables information used in the specific embodiments are shown in the following table:

[0032]

[0033] Instruments used in specific embodiments

[0034] Clean bench, water bath, constant temperature incubator, constant temperature shaker, protein purifier, low temperature high speed centrifuge, developer.

[0035] Identification methods used in specific embodiments

[0036] The detection and identification methods adopted by the present invention are conventional experimental methods: SDS-PAGE, WB, and agarose gel electrophoresis.

[0037] Embodiment 1

[0038] In this embodiment, the schematic diagram of the structure of the key sequence of the plasmid vector is as follows Figure 1 In vivo, three different polypeptides and proteins are simultaneously displayed on the surface of MS2VLP, wherein polypeptide 1 contains Avi Tag (its sequence is shown in SEQ ID NO.7), polypeptide 2 is polyhistidine (its sequence is shown in SEQ ID NO.4), and protein 3 is nanobody N26 (its sequence is shown in SEQ ID NO.8).

[0039] The method for simultaneously displaying three different peptides and proteins on the surface of MS2-VLP is as follows: 1. Construct the vector

[0040] 1. The sequence of the synthetic sequence entrusted to Bioengineering is shown in SEQ ID NO.9, and the vector pBAD-2MS2-T vector is obtained by NcoI and HindIII, and its vector sequence is shown in SEQ ID NO.6. The pBAD-2MS2-T vector displays 3 different polypeptides or proteins, polypeptide 1 contains Avi Tag, polypeptide 2 contains HA Tag, and polypeptide 3 contains Flag Tag. The sequence of the synthetic sequence entrusted to Bioengineering is shown in SEQID NO.10, and it is constructed into the pBAD-2MS2-T vector by AvrII and BglII to obtain the pBAD-2MS2-N26 plasmid vector.

[0041] The schematic diagram of the key sequence of the pBAD-2MS2-N26 plasmid vector is shown in Figure 1As shown, its sequence is shown in SEQ11, containing a packaging sequence, an MS2 phage single-chain dimer CP gene sequence and the coding sequences of polypeptides 1 and 2 to be displayed, a coding sequence of protein 3 and a coding sequence of protein A; the packaging sequence is shown in SEQ ID NO.1, polypeptide 1 is an Avi Tag polypeptide, and its coding sequence is located in the middle of the CP protein single-chain dimer, the amber codon TAG and the coding sequence of polypeptide 2 (containing polyhistidine) are adjacent to the 3' end of the CP protein single-chain dimer coding sequence, the CP gene at least contains a sequence encoding a protein as shown in SEQ ID NO.2, the coding sequence of protein 3 (N26 nanobody) is adjacent to the 5' end of the A protein coding sequence, and the A protein coding sequence is shown in SEQ ID NO.3.

[0042] It contains an arabinose promoter, a packaging sequence, a single-chain dimer CP protein, polypeptide 1 is an Avi Tag polypeptide, polypeptide 2 is a polyhistidine, and there is a linker sequence between polypeptide 2 and the amber codon. The schematic diagram of the structure of the single-chain dimer CP gene and the polypeptide 1 and polypeptide 2 coding sequences, protein 3 and A protein sequence in the sequence shown in SEQ ID NO.11 is shown in Figure 1 As shown, there is a linker sequence between protein 3 and protein A.

[0043] The sequence information shown in SEQ ID NO.11 is as follows (polypeptide 1, polypeptide 2, and protein 3 are marked in the following information):

[0044] (1) Positions 51-392 and 510-851 encode CP protein;

[0045] (2) Positions 393-509 encode polypeptide 1, of which positions 447-491 encode Avi Tag, the Avi Tag sequence is shown in SEQ ID NO.5; the rest is the Avi Tag protein framework.

[0046] (3) Positions 852-854 are the amber codon TAG;

[0047] (4) Positions 855-1061 encode polypeptide 2, wherein positions 855-1043 encode linker and positions 1044-1061 encode polyhistidine, the sequence of which is shown in SEQ ID NO. 4;

[0048] (5) Positions 1085-1103 are the packing sequence.

[0049] (6) 1269-1691 encodes protein 3, specifically N26 nanobody, 1722-2900 encodes protein A, the sequence of protein A is shown in SEQ ID NO.3,

[0050] (7) 1668-1691: Fusion expression of Flag-tagged N26 and protein A carrying a Flag tag

[0051] 2. pBAD-2MS2-N26 vector was transferred into amber mutant strain for expression

[0052] (1) Escherichia coli XL-1-BLUE amber mutant strain was used as the expression host of pBAD-2MS2-N26;

[0053] (2) Purchase competent cells XL-1-BLUE from Weidi Company, and transfer pBAD-2MS2 into XL-1-BLUE according to the instructions, and pick positive colonies for expression;

[0054] (3) Activate the positive colonies overnight, take the overnight bacterial solution and add it to fresh medium containing antibiotics at a ratio of 1:100 for 3 hours, then add arabinose for induction. After 12 hours, recover the bacteria;

[0055] (4) The cells were resuspended in PBS and disrupted by ultrasound. The disrupted liquid was centrifuged at 12,000 g for 10 min, and the supernatant was taken. RNase and DNase were added and digested at 37°C for 30 min. 10 μl of the supernatant was subjected to DNA agarose electrophoresis to identify whether MS2 VLPs were formed.

[0056] 3. Purification and Biotinylation of MS2 VLPs

[0057] (1) purifying the supernatant containing MS2 VLPs by nickel column affinity chromatography;

[0058] (2) The purification instrument was an AKTA avant chromatograph (protein purification system). The purification process was carried out according to the operating instructions, and finally 250 mM imidazole was used to elute to obtain MS2 VLPs;

[0059] (3) The purified MS2 VLPs were biotinylated. The other steps were carried out according to the instructions of the Avi tag protein biotin labeling kit (BirA method) (Shanghai Biotech Co., Ltd.).

[0060] (4) Identification of MS2 VLPs by SDS-PAGE and Western Blot (WB).

[0061] 4. Result detection:

[0062] (1) pBAD-2MS2-N26 vector was transformed into E. coli XL-1-BLUE and induced to express by arabinose. Figure 2As shown in A: After the supernatant of the broken bacteria was digested with RNase and DNase after expression, there was a clear band at 1000 bp, which indicated that pBAD-2MS2-N26 could form MS2 VLP in XL-1-BLUE.

[0063] (2) The supernatant containing MS2 VLP was purified by nickel column affinity chromatography, and the purified sample was eluted with 250 mM imidazole and identified by SDS-PAGE and WB. Figure 2 As shown in B, the 250mM imidazole elution peak sample has obvious bands between 25-33Kda, which is consistent with the expectation of single-chain dimer protein, and there is a band near 72Kda, which is consistent with the expectation of N26-A protein. Figure 2 As shown in C, it is further proved that the 25-33Kda band is detected by streptavidin-HRP and carries biotin, and the band near 72Kda is detected by anti-Flag antibody and carries Flag tag. The above test results show that the surface of MS2 VLP displays three kinds of peptides or proteins at the same time, carries biotin and displays nanoantibody N26.

[0064] [1]Fu Y, Li JA novel delivery platform based on Bacteriophage MS2virus-like particles. Virus Res. 2016; 211:9-16.

[0065] [2] Hashemi K, Ghahramani Seno MM, Ahmadian MR, Malaekeh-Nikouei B, Bassami MR, Dehghani H, Afkhami-Goli A. Optimizing the synthesis and purification of MS2 virus like particles. Sci Rep. 2021 Oct 6; 11(1): 19851.

[0066] [3] Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013; 82: 775-97.

[0067] [4] Weiss RA, Verrips CT. Nanobodies that Neutralize HIV. Vaccines (Basel). 2019Jul 31;7(3):77.

[0068] [5]de Marco A.Recombinant expression of nanobodies and nanobody-derived immunoreagents.Protein Expr Purif.2020Aug;172:105645.

[0069] [6]Zakeri B,Fierer JO,Celik E,Chittock EC,Schwarz-Linek U,Moy VT,Howarth M.Peptide tag forming a rapid covalent bond to a protein,throughengineering abacterial adhesin.Proc Natl Acad Sci U S A.2012Mar 20;109(12):E690-7.

[0070] [7]Tian J,Jia R,Wenge D,Sun H,Wang Y,Chang Y,Luo H.One-steppurification and immobilization of recombinant proteins using SpyTag / SpyCatcher chemistry.Biotechnol Lett.2021May;43(5):1075-1087.

[0071] [8]Wang W,Liu Z,Zhou X,Guo Z,Zhang J,Zhu P,Yao S,Zhu M.Ferritinnanoparticle-based SpyTag / SpyCatcher-enabled click vaccine for tumor immunotherapy.Nanomedicine.2019Feb;16:69-78。

Claims

1. A plasmid vector, characterized in that: The plasmid vector contains at least a packaging sequence, an MS2 phage single-chain dimer CP gene sequence, and coding sequences of polypeptides 1 and 2 to be displayed, a coding sequence of protein 3, and a coding sequence of protein A; the packaging sequence is as shown in SEQ ID NO.1, the coding sequence of polypeptide 1 is located in the middle of the CP protein single-chain dimer, the amber codon TAG and the coding sequence of polypeptide 2 are adjacent to the 3' end of the CP protein single-chain dimer coding sequence, the CP gene at least contains a sequence encoding a protein as shown in SEQ ID NO.2, the coding sequence of protein 3 is adjacent to the 5' end of the coding sequence of protein A, and the sequence of protein A is as shown in SEQ ID NO.

3.

2. The plasmid vector according to claim 1, characterized in that: The carboxyl-terminal fusion purification tag polyhistidine of the polypeptide 2 coding sequence is shown in SEQ ID NO.

4.

3. The plasmid vector according to claim 1, characterized in that: A linker sequence is added between the amber codon TAG and the coding sequence of polypeptide 2, and the amino acid encoded by the linker sequence contains glycine.

4. The plasmid vector according to claim 1, characterized in that: The 5' ends of the coding sequences of the MS2 phage single-chain dimer CP gene and the polypeptide 1 and polypeptide 2 to be displayed have a promoter.

5. The plasmid vector according to claim 1, characterized in that: A linker sequence is added between the protein 3 and the A protein, and the amino acid encoded by the linker sequence contains glycine.

6. The plasmid vector according to claim 1, characterized in that: The sequence of the plasmid vector is shown in SEQ ID NO.

6.

7. The plasmid vector according to claim 1, characterized in that: The sequence encoded by the polypeptide 1 contains the Avi Tag encoding sequence shown as SEQ ID NO.

7.

8. A method for displaying three polypeptides or proteins on the surface of MS2 VLP, characterized in that: The following steps are involved: (1) constructing a plasmid vector as described in any one of claims 1 to 7; (2) The plasmid vector constructed in step (1) is transferred into competent cells for expression to obtain MS2 VLPs displaying polypeptide 1, polypeptide 2 and protein 3 on the surface.

9. The method for displaying three polypeptides or proteins on the surface of MS2 VLP according to claim 8, characterized in that: The competent cells in step (2) are amber mutant Escherichia coli.

10. The method for displaying three polypeptides or proteins on the surface of MS2 VLP according to claim 7, characterized in that: When step (1) constructs the plasmid vector as claimed in claim 7, it also includes the following steps: (3) The bacterial cells of step (2) are crushed, and the supernatant is purified by nickel column to obtain MS2 VLP; (4) The purified MS2 VLPs were biotinylated in vitro using BirA enzymatic reaction.